Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Maschmeyer

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Haematology and Blood Transfusion|January 1, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapseT Büchner, W Hiddemann, M Koenigsmann, et al.
Bone Marrow Transplantation|July 1, 1990
Recombinant human GM-CSF following chemotherapy in high-risk AMLT Buechner, W Hiddemann, M Koenigsmann, et al.
Blood|September 1, 1991
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapseT Büchner, W Hiddemann, M Koenigsmann, et al.
Onkologie|February 1, 1989
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary resultsW Hiddemann, C Aul, G Maschmeyer, et al.
Annals of Hematology|October 31, 1998
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative GroupW Kern, C Aul, G Maschmeyer, et al.
Leukemia|January 1, 1992
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCGT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia|July 17, 1998
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonW Kern, C Aul, G Maschmeyer, et al.
Leukemia|September 1, 1990
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)W Hiddemann, T Büchner, G Heil, et al.
Infection|March 1, 1988
Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopeniaG Maschmeyer, E Haralambie, W Gaus, et al.
Annals of Hematology|November 28, 2017
Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)M Schmidt-Hieber, J Bierwirth, D Buchheidt, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Haematology and Blood Transfusion|January 1, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapseT Büchner, W Hiddemann, M Koenigsmann, et al.
Bone Marrow Transplantation|July 1, 1990
Recombinant human GM-CSF following chemotherapy in high-risk AMLT Buechner, W Hiddemann, M Koenigsmann, et al.
Blood|September 1, 1991
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapseT Büchner, W Hiddemann, M Koenigsmann, et al.
Onkologie|February 1, 1989
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary resultsW Hiddemann, C Aul, G Maschmeyer, et al.
Annals of Hematology|October 31, 1998
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative GroupW Kern, C Aul, G Maschmeyer, et al.
Leukemia|January 1, 1992
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCGT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia|July 17, 1998
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonW Kern, C Aul, G Maschmeyer, et al.
Leukemia|September 1, 1990
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)W Hiddemann, T Büchner, G Heil, et al.
Infection|March 1, 1988
Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopeniaG Maschmeyer, E Haralambie, W Gaus, et al.
Annals of Hematology|November 28, 2017
Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)M Schmidt-Hieber, J Bierwirth, D Buchheidt, et al.
Pageof 9